Pharmacokinetics, Pharmacodynamics, and Safety of Lisinopril in Pediatric Kidney Transplant Patients: Implications for Starting Dose Selection.

Journal Article (Clinical Trial;Journal Article)

Hypertension in pediatric kidney transplant recipients contributes to long-term graft loss, yet treatment options--including angiotensin-converting enzyme inhibitors--are poorly characterized in this vulnerable population. We conducted a multicenter, open-label pharmacokinetic (PK) study of daily oral lisinopril in 22 children (ages 7-17 years) with stable kidney transplant function. Standard noncompartmental PK analyses were performed at steady state. Effects on blood pressure were examined in lisinopril-naïve patients (n = 13). Oral clearance declined in proportion to underlying kidney function; however, in patients with low estimated glomerular filtration rate (30-59 ml/min per 1.73m(2)), exposure (standardized to 0.1 mg/kg/day dose) was within the range reported previously in children without a kidney transplant. In lisinopril-naïve patients, 85% and 77% had a ≥ 6 mmHg reduction in systolic and diastolic blood pressure, respectively. Lisinopril was well tolerated. Our study provides initial insight on lisinopril use in children with a kidney transplant, including starting dose considerations.

Full Text

Duke Authors

Cited Authors

  • Trachtman, H; Frymoyer, A; Lewandowski, A; Greenbaum, LA; Feig, DI; Gipson, DS; Warady, BA; Goebel, JW; Schwartz, GJ; Lewis, K; Anand, R; Patel, UD; Best Pharmaceuticals for Children Act-Pediatric Trials Network Administrative Core Committee,

Published Date

  • July 2015

Published In

Volume / Issue

  • 98 / 1

Start / End Page

  • 25 - 33

PubMed ID

  • 25807932

Pubmed Central ID

  • PMC4536255

Electronic International Standard Serial Number (EISSN)

  • 1532-6535

Digital Object Identifier (DOI)

  • 10.1002/cpt.127


  • eng

Conference Location

  • United States